UNSPSC 51453005: Piperazine citrate

This classification denotes an antihelminthic agent with the molecular formula 2C6H8O7.3C4H10N2.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 63KP7FXF2I, chemically known as 1,4-piperazine but more generally known as piperazine citrate, which bears US NIH Compound Identifier 4837. European Medicines Agency schedules Piperazine citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14884MIG.

Most nations, for tariff and trade purposes, schedule piperazine citrate under HS 29335990 and SITC 51576. As of Q4 2014, PIPERAZINE CITRATE remains US FDA's Preferred Term for this commodity. Piperazine citrate bears US NLM identifiers UMLS ID C1145666 and NCI Concept Code C47674. SMILES: C1CNCCN1.C1CNCCN1.C1CNCCN1.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.O.

UNSPSC 51453005 Piperazine citrate is a Commodity code that sees limited recent state and local procurement activity. The recent opportunities tagged to this code do not align with the code's nominal scope — the Illinois Department of Public Health's August 28, 2026 pharmaceutical warehouse piggyback award involved Doxycycline Hyclate and Ciprofloxacin Hydrochloride, neither of which is piperazine citrate, and Seminole County, Florida's June 30, 2026 naloxone procurement addresses emergency medical supplies unrelated to the code's stated product. State and local governments rarely solicit piperazine citrate directly; when pharmaceutical codes appear in procurement databases, the actual products purchased often diverge from the code's specification.

The code shows no active open solicitations and no clear issuing-body pattern or geographic concentration supporting pursuit decisions. Procurement professionals should verify whether state and local health agencies, corrections departments, or public health warehouses in their target markets maintain standing contracts or cooperative purchasing agreements for this product through pharmacy benefit managers or pharmaceutical distributors, as direct solicitations under this code are not evident in current activity.